Meeting
2019 ASCO Annual Meeting
KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma.
Authors
Jessica Lyn Geiger
Cleveland Clinic, Cleveland, OH
Jessica Lyn Geiger , Gregory A. Daniels , Ezra E.W. Cohen , Joy Yang Ge , Burak Gumuscu , Ramona F. Swaby , Anne Lynn S. Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03833167
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS9597)
DOI
10.1200/JCO.2019.37.15_suppl.TPS9597
Abstract #
TPS9597
Poster Bd #
166b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin
Poster
2020 ASCO Virtual Scientific Program
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin
Poster
2018 ASCO Annual Meeting
Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
First Author: Jean-Pascal H. Machiels
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson